Pharmaceutical
Learn about the latest developments in the pharmaceutical cannabis industry with Business of Cannabis. Discover new drugs, research, and more.
Pharmaceutical · page 15
- Pharmaceutical
Agreements to advance chronic pain relief for trigeminal neuralgia
Oxford Cannabinoid Technologies has signed agreements to accelerate the development of a pain management solution using phytocannabinoids.
- Pharmaceutical
Plans Unveiled For First National Health Service-Backed Medical Cannabis Clinical Trial
AFTER launching a patient registry earlier this year further signs the UK’s National Health Service is warming to cannabis medicine have emerged with news of the potential launch of a clinical trial.
- Pharmaceutical
Exclusive derivative library licence for Oxford Cannabinoid Technologies
Oxford Cannabinoid Technologies has signed a worldwide exclusive licence agreement with Canopy Growth Corporation.
- Pharmaceutical
Oxford Cannabinoid Technologies Holdings Sign Exclusive Worldwide License Agreement With Canopy Growth
Oxford Cannabinoid Technologies Holdings plc (OCTP), the holding company of Oxford Cannabinoid Technologies Ltd (“OCT”) (together, the “Group”), a company developing licensed prescription cannabinoid medicines for approval by regulatory agencies worldwide and targeting the U$ multi-billion pain market, is pleased to announce that on 21 September 2021 OCT signed an exclusive licensing agreement with Canopy…
- Cultivation
With Global Cannabis Cultivation Capacity Set To Outstrip Demand One Hundredfold – What Happened To The ‘Green’ Rush?
CANNABIS investors need to be wary when it comes to cultivation, says Oliver Zugel, Founder and CEO FoliuMed Holdings.
- Pharmaceutical
Greek Cannabis Cultivator Waiting For Regulator’s Approval Before A SPAC London Listing
HELLENIC Dynamics is aiming to become the first medical cannabis cultivator to list on the London Stock Exchange.
- Pharmaceutical
Cannabis-based pharmaceuticals offer “major opportunities”, says new report
A new industry report has highlighted the huge “untapped” potential of cannabis-based pharmaceuticals.
- Pharmaceutical
Sales Of Three Major Pharmaceutical Cannabis Products Set To Reach €1.8 Billion By 2025
COMBINED sales of the three most lucrative cannabis pharmaceuticals products – Epidiolex, Dronabinol and Sativex – are set to reach €1.8 billion by 2025, according to a new report.
- Pharmaceutical
Oxford Cannabinoid Technologies applies for admission to OTC QB Market
Oxford Cannabinoid Technologies has applied to be admitted to the OTC QB Market in the United States.
- CBD Market
Epidyolex receives approval for tuberous sclerosis seizures treatment
The approval applies in England, Wales and Scotland and follows the recent approval of the product in all 27 countries of the European Union.
- CBD Market
UK Tobacco Giant BAT Makes Third Cannabis Investment As It Moves Beyond Nicotine
UK tobacco giant BAT has followed up its £127m investment into Organigram with further investment in a Canadian cannabis company.
- Pharmaceutical
Oxford Cannabinoid Technologies Holdings Post IPO Review
OXFORD Cannabinoid Technologies Holdings plc (“OCTP” or the “Company”), the holding company of Oxford Cannabinoid Technologies Ltd (“OCT”) (together the “Group”), a UK pharmaceutical company focussed on developing a portfolio of cannabinoid-based prescription medicines, approved by medicines regulatory agencies which target the pain market, is pleased to provide an update following its £16.5 million fundraise…
